Advertisement

Febuxostat, a novel inhibitor of xanthine oxidase, reduces ER stress through upregulation of SIRT1-AMPK-HO-1/thioredoxin expression

  • Hyosang Kim
  • Chung Hee Baek
  • Jai Won Chang
  • Won Seok Yang
  • Sang Koo LeeEmail author
Original article
  • 71 Downloads

Abstract

Background

Endoplasmic reticulum (ER) stress has been implicated in the development of various renal diseases. Thus, inhibition of ER stress using pharmacological agents may serve as a promising therapeutic approach. We postulated that febuxostat, a novel xanthine oxidase inhibitor, could suppress the ER stress through upregulation of SIRT1 (silent mating type information regulation 2 homolog 1)-AMPK (AMP activated protein kinase)-HO-1 (heme oxygenase-1)/thioredoxin expression.

Methods

We examined the effect of febuxostat on the ER stress induced by a chemical inducer, tunicamycin and non-chemical agents such as angiotensin II, aldosterone, high glucose, and albumin in renal tubular cells. We further examined the in vivo effects of febuxostat using mouse model of kidney disease induced by unilateral ureteral obstruction (UUO). Expression of ER stress was measured by western blot analysis and immunohistochemical stain.

Results

Febuxostat suppressed the ER stress induced by tunicamycin and non-chemical agents, as shown by inhibition of increased GRP78 (glucose-related protein78) and p-eIF2α (phosphospecific-eukaryotic translation initiation factor 2α) expression. Inhibitory effect of febuxostat was mediated through upregulation of SIRT1-AMPK followed by induction of HO-1 and thioredoxin. In animal model of UUO, febuxostat reduced the UUO-induced ER stress, which was abolished by pretreatment with SIRT1 inhibitor (sirtinol) and AMPK inhibitor (compound C).

Conclusion

Febuxostat could suppress the ER stress caused by various ER stress inducers through upregulation of SIRT1-AMPK-HO-1/thioredoxin expression. Targeting these pathways might serve as one of the possible therapeutic approaches in kidney diseases under excessive ER stress.

Keywords

AMPK ER stress Febuxostat HO-1 SIRT1 Thioredoxin 

Notes

Acknowledgements

Reprints request to Sang Koo Lee M.D., Division of Nephrology, Department of Internal Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. E-mail: sklee2@amc.seoul.kr.

Funding

No funding received.

Compliance with ethical standards

Conflict of interest

All the authors have declared no competing interest.

Ethical approval

All procedures performed in animal experiments were approved by Institutional Animal Care and Use Committee of Asan Institute for Life Sciences (Subject No: 2017-13-039).

References

  1. 1.
    Cybulsky AV. Endoplasmic reticulum stress in proteinuric kidney disease. Kidney Int. 2010;77:7–193.CrossRefGoogle Scholar
  2. 2.
    Tanjore H, Lawson WE, Blackwell TS. Endoplasmic reticulum stress as a pro-fibrotic stimulus. Biochim Biophys Acta. 2013;1832(7):940–7.CrossRefGoogle Scholar
  3. 3.
    Cybulsky AV. Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases. Nat Rev Nephrol. 2017;13(11):681–96.CrossRefGoogle Scholar
  4. 4.
    Julee PS, Deepa RP, Dhrubo JS. Febuxostat: the new generation novel xanthine oxidase inhibitors. Int Pharm Sci. 2011;1:107–15.Google Scholar
  5. 5.
    Sanchez-Lozada LG, Tapia E, Soto V, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 2008;108:69–788.CrossRefGoogle Scholar
  6. 6.
    Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427:266–72.CrossRefGoogle Scholar
  7. 7.
    Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16:549–56.CrossRefGoogle Scholar
  8. 8.
    Kim HS, Lim SW, Jin L, Jin J, Chung BH, Yang CW. The protective effect of febuxostat on chronic tacrolimus induced nephrotoxicity in rats. Nephron. 2017;135(1):61–71.CrossRefGoogle Scholar
  9. 9.
    Kitada M, Kume S, Koya D. Role of sirtuins in kidney disease. Curr Opin Nephrol Hypertens. 2014;23(1):75–9.CrossRefGoogle Scholar
  10. 10.
    Fisslhaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res. 2009;105:114–27.CrossRefGoogle Scholar
  11. 11.
    Lee MJ, Feliers D, Mariappan MM, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Ren Physiol. 2007;292(2):F617–27.CrossRefGoogle Scholar
  12. 12.
    Morales AI, Detaille D, Prieto M, et al. Metformin prevents experimental gentamycin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 2010;77(10):861–9.CrossRefGoogle Scholar
  13. 13.
    Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA. 2011;108(6):2462–7.CrossRefGoogle Scholar
  14. 14.
    Kirkby KA, Adin CA. Products of heme oxygenase and their potential therapeutic applications. Am J Physiol Ren Physiol. 2006;290:F563–71.CrossRefGoogle Scholar
  15. 15.
    Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res. 2003;93(11):1029–33.CrossRefGoogle Scholar
  16. 16.
    Chung J, Shin DY, Zheng M, et al. Carbon monoxide, a reaction product of heme oxygenase-1, suppresses the expression of C-reactive protein by endoplasmic reticulum stress through modulation of the unfolded protein response. Mol Immunol. 2011;48(15–16):1793–9.CrossRefGoogle Scholar
  17. 17.
    Kim Y, Li E, Park S. Insulin-like growth factor-1 inhibits 6-hydroxydopamine-mediated endoplasmic reticulum stress-induced apoptosis via regulation of heme oxygenase-1 and Nrf2 expression in PC12 cells. Int J Neurosci. 2012;122(11):641–9.CrossRefGoogle Scholar
  18. 18.
    Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 1994;45(1):48–57.CrossRefGoogle Scholar
  19. 19.
    Kim H, Moon SY, Kim JS, et al. Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis. Am J Physiol Ren Physiol. 2015;308(3):F226–36.CrossRefGoogle Scholar
  20. 20.
    Pimentel JL Jr, Sundell CL, Wang S, Kopp JB, Montero A, Martinez-Maldonado M. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int. 1995;48(4):1233–46.CrossRefGoogle Scholar
  21. 21.
    Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS. Prevention of renal fibrosis by spironolactone in mice withy complete unilateral ureteral obstruction. J Urol. 2004;172(4 Pt 2):1590–4.CrossRefGoogle Scholar
  22. 22.
    He L, Fan Y, Xiao W, et al. Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy. Oncotarget. 2017;8(67):111295–308.CrossRefGoogle Scholar
  23. 23.
    Hao CM, Haase VH. Sirtuins and their relevance to the kidney. J Am Soc Nephrol. 2010;21(10):1620–7.CrossRefGoogle Scholar
  24. 24.
    Lee EK, Jeong JU, Chang JW, et al. Activation of AMP-activated protein kinase inhibits albumin-induced endoplasmic reticulum stress and apoptosis through inhibition of reactive oxygen species. Nephron Exp Nephrol. 2012;121:e38–48.CrossRefGoogle Scholar
  25. 25.
    Thériault JR, Palmer HJ, Pittman DD. Inhibition of the unfolded protein response by metformin in renal proximal tubular epithelial cells. Biochem Biophys Res Commun. 2011;409(3):500–5.CrossRefGoogle Scholar
  26. 26.
    Ruderman NB, Xu XJ, Nelson L, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. 2010;298(4):E51–60.CrossRefGoogle Scholar
  27. 27.
    Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem. 2008;283(41):27628–35.CrossRefGoogle Scholar
  28. 28.
    Sato Y, Feig DI, Stack AG, et al. The case for uric acid-lowering treatment in patients with hyperuricemia and CKD. Nat Rev Nephrol. 2019.  https://doi.org/10.1038/s41581-019-0174-z.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Division of Nephrology, Department of Internal Medicine, Asan Medical Center, Asan Institute for Life SciencesUniversity of UlsanSeoulKorea

Personalised recommendations